+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alopecia Treatment Market by Drug Type, Indication, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • PDF Icon

    Report

  • 243 Pages
  • January 2020
  • Region: Global
  • Allied Market Research
  • ID: 5021795
The global alopecia treatment market was valued at $2,736 million in 2018, and is projected to reach $3,935 million by 2026, registering a CAGR of 4.6% from 2019 to 2026. Alopecia is a term used to describe extreme hair loss or hair damage under certain dietary issues and medical conditions. It is a common autoimmune disease, which causes bald spots resulting in partial or complete hair loss. It can affect persons of all gender and at any stage of life, it commonly affects mid-aged generation. Various hair transplant therapies and drugs can be used for the treatment of alopecia condition. Treatment of alopecia condition can be carried out using drugs such as minoxidil, finasteride, and other drugs.



Significant increase in prevalence of chronic diseases such as hypertension, arthritis, Polycystic Ovary Syndrome (PCOS), and depression; rise in geriatric population; hormonal imbalance; high level of stress; increase in consumption of alcohol & tobacco, change in food habits, and an increase in prevalence of chemotherapy induced alopecia fuel the growth of the alopecia treatment market. Moreover, rise in awareness programs for alopecia treatment & management; increase in prevalence of alopecia conditions such as androgenic alopecia, alopecia areata, alopecia totalis, and others; and genetic factors might contribute toward rise in incidences of alopecia among both men & women are other factors that contribute toward the growth of the market. However, poor demand for alopecia treatment drugs in underdeveloped countries are expected to hinder the growth of the market.

The alopecia treatment market is segmented into drug type, indication, distribution channel, and region. By drug type, the market is categorized into minoxidil, finasteride, and other drug types. The indication covered in the study include androgenic alopecia, alopecia areata, alopecia totalis, and others. Depending on the distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Type
  • Minoxidil
  • Finasteride
  • Other Drug Types

By Indication
  • Androgenic Alopecia
  • Alopecia Areata
  • Alopecia Totalis
  • Others

By End User
  • Hospitals Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Capillus, LLC
  • Cipla Inc.
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Transitions Hair
  • Vitabiotics Ltd.
  • Vita-Cos-Med Klett-Loch GmbH

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Dr. Reddy's Laboratories
  • Concert Pharmaceuticals Inc.
  • Aclaris Therapeutics, Inc.

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter's Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Increase In Chronic Diseases To Lead To Hair Loss
3.4.1.2. Surge In Global Geriatric Population
3.4.1.3. Increase In Government Expenditure On Healthcare
3.4.2. Restraint
3.4.2.1. Poor Demand In Under Developed Countries
3.4.3. Opportunities
3.4.3.1. Growth Opportunities In Emerging Markets
3.4.4. Impact Analysis
Chapter 4: Alopecia Treatment Market, By Drug Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Minoxidil
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Finasteride
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Other Drug Types
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
Chapter 5: Alopecia Treatment Market, By Indication
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Androgenic Alopecia
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Alopecia Areata
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
5.4. Alopecia Totalis
5.4.1. Market Size And Forecast
5.4.2. Market Analysis, By Country
5.5. Others
5.5.1. Market Size And Forecast
5.5.2. Market Analysis, By Country
Chapter 6: Alopecia Treatment Market, By Distribution Channel
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Hospitals Pharmacies
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Drug Stores & Retail Pharmacies
6.3.1. Market Size And Forecast
6.3.2. Market Analysis, By Country
6.4. Online Pharmacies
6.4.1. Market Size And Forecast
6.4.2. Market Analysis, By Country
Chapter 7: Alopecia Treatment Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Alopecia Treatment Market, By Drug Type
7.2.2.1.2. U.S. Alopecia Treatment Market, By Indication
7.2.2.1.3. U.S. Alopecia Treatment Market, By Distribution Channel
7.3. North America
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.2.1. U.S.
7.3.2.1.1. U.S. Alopecia Treatment Market, By Drug Type
7.3.2.1.2. U.S. Alopecia Treatment Market, By Indication
7.3.2.1.3. U.S. Alopecia Treatment Market, By Distribution Channel
7.3.2.2. Canada
7.3.2.2.1. Canada Alopecia Treatment Market, By Drug Type
7.3.2.2.2. Canada Alopecia Treatment Market, By Indication
7.3.2.2.3. Canada Alopecia Treatment Market, By Distribution Channel
7.3.2.3. Mexico
7.3.2.3.1. Mexico Alopecia Treatment Market, By Drug Type
7.3.2.3.2. Mexico Alopecia Treatment Market, By Indication
7.3.2.3.3. Mexico Alopecia Treatment Market, By Distribution Channel
7.3.3. North America Market Size And Forecast, By Drug Type
7.3.4. North America Market Size And Forecast, By Indication
7.3.5. North America Market Size And Forecast, By Distribution Channel
7.4. Europe
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.2.1. Germany
7.4.2.1.1. Germany Alopecia Treatment Market, By Drug Type
7.4.2.1.2. Germany Alopecia Treatment Market, By Indication
7.4.2.1.3. Germany Alopecia Treatment Market, By Distribution Channel
7.4.2.2. France
7.4.2.2.1. France Alopecia Treatment Market, By Drug Type
7.4.2.2.2. France Alopecia Treatment Market, By Indication
7.4.2.2.3. France Alopecia Treatment Market, By Distribution Channel
7.4.2.3. UK
7.4.2.3.1. UK Alopecia Treatment Market, By Drug Type
7.4.2.3.2. UK Alopecia Treatment Market, By Indication
7.4.2.3.3. UK Alopecia Treatment Market, By Distribution Channel
7.4.2.4. Italy
7.4.2.4.1. Italy Alopecia Treatment Market, By Drug Type
7.4.2.4.2. Italy Alopecia Treatment Market, By Indication
7.4.2.4.3. Italy Alopecia Treatment Market, By Distribution Channel
7.4.2.5. Spain
7.4.2.5.1. Spain Alopecia Treatment Market, By Drug Type
7.4.2.5.2. Spain Alopecia Treatment Market, By Indication
7.4.2.5.3. Spain Alopecia Treatment Market, By Distribution Channel
7.4.2.6. Rest of Europe
7.4.2.6.1. Rest of Europe Alopecia Treatment Market, By Drug Type
7.4.2.6.2. Rest of Europe Alopecia Treatment Market, By Indication
7.4.2.6.3. Rest of Europe Alopecia Treatment Market, By Distribution Channel
7.4.3. Europe Market Size And Forecast, By Drug Type
7.4.4. Europe Market Size And Forecast, By Indication
7.4.5. Europe Market Size And Forecast, By Distribution Channel
7.5. Asia-Pacific
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.2.1. Japan
7.5.2.1.1. Japan Alopecia Treatment Market, By Drug Type
7.5.2.1.2. Japan Alopecia Treatment Market, By Indication
7.5.2.1.3. Japan Alopecia Treatment Market, By Distribution Channel
7.5.2.2. China
7.5.2.2.1. China Alopecia Treatment Market, By Drug Type
7.5.2.2.2. China Alopecia Treatment Market, By Indication
7.5.2.2.3. China Alopecia Treatment Market, By Distribution Channel
7.5.2.3. Australia
7.5.2.3.1. Australia Alopecia Treatment Market, By Drug Type
7.5.2.3.2. Australia Alopecia Treatment Market, By Indication
7.5.2.3.3. Australia Alopecia Treatment Market, By Distribution Channel
7.5.2.4. India
7.5.2.4.1. India Alopecia Treatment Market, By Drug Type
7.5.2.4.2. India Alopecia Treatment Market, By Indication
7.5.2.4.3. India Alopecia Treatment Market, By Distribution Channel
7.5.2.5. South Korea
7.5.2.5.1. South Korea Alopecia Treatment Market, By Drug Type
7.5.2.5.2. South Korea Alopecia Treatment Market, By Indication
7.5.2.5.3. South Korea Alopecia Treatment Market, By Distribution Channel
7.5.2.6. Rest of Asia-Pacific
7.5.2.6.1. Rest of Asia-Pacific Alopecia Treatment Market, By Drug Type
7.5.2.6.2. Rest of Asia-Pacific Alopecia Treatment Market, By Indication
7.5.2.6.3. Rest of Asia-Pacific Alopecia Treatment Market, By Distribution Channel
7.5.3. Asia-Pacific Market Size And Forecast, By Drug Type
7.5.4. Asia-Pacific Market Size And Forecast, By Indication
7.5.5. Asia-Pacific Market Size And Forecast, By Distribution Channel
7.6. LAMEA
7.6.1. Key Market Trends, Growth Factors, And Opportunities
7.6.2. Market Size And Forecast, By Country
7.6.2.1. Brazil
7.6.2.1.1. Brazil Alopecia Treatment Market, By Drug Type
7.6.2.1.2. Brazil Alopecia Treatment Market, By Indication
7.6.2.1.3. Brazil Alopecia Treatment Market, By Distribution Channel
7.6.2.2. Saudi Arabia
7.6.2.2.1. Saudi Arabia Alopecia Treatment Market, By Drug Type
7.6.2.2.2. Saudi Arabia Alopecia Treatment Market, By Indication
7.6.2.2.3. Saudi Arabia Alopecia Treatment Market, By Distribution Channel
7.6.2.3. South Africa
7.6.2.3.1. South Africa Alopecia Treatment Market, By Drug Type
7.6.2.3.2. South Africa Alopecia Treatment Market, By Indication
7.6.2.3.3. South Africa Alopecia Treatment Market, By Distribution Channel
7.6.2.4. Rest of LAMEA
7.6.2.4.1. Rest of LAMEA Alopecia Treatment Market, By Drug Type
7.6.2.4.2. Rest of LAMEA Alopecia Treatment Market, By Indication
7.6.2.4.3. Rest of LAMEA Alopecia Treatment Market, By Distribution Channel
7.6.3. LAMEA Market Size And Forecast, By Drug Type
7.6.4. LAMEA Market Size And Forecast, By Indication
7.6.5. LAMEA Market Size And Forecast, By Distribution Channel

Executive Summary

According to the report, titled, 'Alopecia Treatment Market by Drug Type, Indication, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global alopecia treatment market size was valued at $2,736 million in 2018, and is projected to reach $3,935 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026.

Alopecia, also known as hair loss or baldness, refers to hair loss from the part of head or body. The condition can happen in both female & male and at any age. There are five major kind of alopecia to be specific such as androgenic alopecia, alopecia areata, alopecia totalis, cicatricial alopecia, and telogen effluvium. Alopecia areata is an autoimmune disorder, which attacks the hair follicles and causes hair fall or breakage of hair leading to complete baldness. The cause of male-pattern alopecia and female-pattern alopecia include hormonal changes, hereditary condition, radiation therapy to the head, stress, and certain medications & supplements. Alopecia treatment plays a main role in advanced healthcare, as it helps in prevention of hair fall and regrowth of hair. Treatment for hair loss can be carried out using drugs such as minoxidil, finasteride, 5-alpha-reductase inhibitors, corticosteroids, and cyclosporine. Moreover, surgical treatments for alopecia include hair transplantation, scalp reduction, and laser therapy.

The alopecia treatment market is expected to experience significant growth during the forecast period, owing to surge in geriatric population; rise in prevalence of alopecia conditions such as androgenic alopecia, alopecia areata, alopecia totalis, and others; and an increase in prevalence of chemotherapy induced alopecia. In addition, high level of stress, hormonal imbalance, increase in consumption of alcohol & tobacco, and change in food habits further drives the market growth.

Based on drug type, the market is categorized into minoxidil, finasteride, and other drug types. Presently, minoxidil dominates the global market, and is anticipated to continue this trend during the forecast period. The key factors that drive the market growth include surge in demand for minoxidil drug for alopecia treatment; rise in prevalence of chronic diseases such as arthritis, depression, hypertension, and cancer treatment that tend to hair loss from patient body; and an increase in air & water pollution that harms the health of the hair and cause baldness & early breakage.

Based on indication, the global alopecia treatment market is segmented into androgenic alopecia, alopecia areata, alopecia totalis, and others. Currently, the androgenic alopecia segment accounted for the majority of the market share, owing to rise in incidence of androgenic alopecia condition, unhealthy lifestyle, hormonal imbalance and an increase in geriatric population across the globe. The alopecia totalis is fastest growing segment at a CAGR of 5.5% from 2019 to 2026, owing to rise in incidence of alopecia totalis condition, surge in patient awareness regarding the alopecia totalis disorder, and an increase in geriatric population.

Key Findings of the Study
Based on drug type, the minoxidil segment held more than 44.35% share in the global market in 2018.
By indication, the androgenic alopecia segment accounted for the largest market share in 2018, and is expected to remain dominant throughout the forecast period.
Based on the distribution channel, the drug stores & retail pharmacies segment held 58.27% share in the global market in 2018.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 5.9% during the forecast period.
North America accounted for approximately one-half of the global alopecia treatment market share in 2018 and is expected to remain dominant throughout the forecast period. This was attributed to the higher adoption of alopecia treatment products, large presence of pharmaceutical companies, well developed healthcare infrastructure, and wide availability of advanced alopecia treatment products. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, the developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare.

Companies Mentioned

  • Capillus LLC
  • Cipla Inc.
  • Daiichi Sankyo Company
  • Limited
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Transitions Hair
  • Vitabiotics Ltd.
  • Vita-Cos-Med Klett-Loch GmbH.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information